Stéphane Boulé

Stéphane Boulé

Auto-generated profile, based on publicly available information

Stéphane Boulé

Lille University Hospital, Department of Cardiovascular Medicine, Lille, France

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2014 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
LGLaurence Guédon‐Moreau
Laurence Guédon‐Moreau
CKClaude Kouakam
Claude Kouakam
DKDidier Klug
Didier Klug
CMChristelle Marquié
Christelle Marquié
FBFrançois Brigadeau
François Brigadeau
SKSalem Kacet
Salem Kacet

3 March 2014 in EP Europace
Verified
Journal Article
Open access
PDF file
SBStéphane Boulé
Stéphane Boulé
LOLionel Ovart
Lionel Ovart
CMChristelle Marquié
Christelle Marquié
EBEdward Botcherby
Edward Botcherby
DKDidier Klug
Didier Klug
SKSalem Kacet
Salem Kacet
To describe obstetric/neonatal and cardiac outcomes for a cohort of women carrying implantable cardioverter-defibrillators (ICDs) during pregnancy. All women in routine follow-up at our institution for ICD implantation who became pregnant between 2006 and 2013 were included in this study. All ICDs were pre-pectoral devices with bipolar endocardial leads. Obstetric/neonatal and cardiac outcomes were assessed during pregnancy and post-partum. Twenty pregnancies were conceived by 12 women carrying ICD devices, 14 of which resulted in live births and none in maternal death. Seven of these women had structural cardiomyopathies and five had channelopathies. No device-related complications were recorded. Twelve shocks (nine transthoracic and three from ICDs) were experienced during pregnancy by two women, one of whom miscarried shortly afterwards at 4 weeks gestation. One stillbirth, three miscarriages and one termination were recorded for women with long QT syndrome, repaired tetralogy of Fallot and repaired Laubry–Pezzi syndrome, respectively. Intrauterine growth restriction, low birth weight, and neonatal hypoglycaemia were recorded in four, three, and five pregnancies, respectively. Pregnancy had no effect on ICD operation and no evidence was found to link ICD carriage with adverse pregnancy outcomes, although one miscarriage may have been induced by ICD shock therapy. A worsening of cardiac condition occurs in specific cardiac diseases and β-blocker therapy should be continued for all women carrying ICDs in pregnancy as the benefits outweigh the risks of taking this medication.

24 December 2016 in EP Europace
Verified
Journal Article
Closed access
PDF file
ZSZouheir Souissi
Zouheir Souissi
SBStéphane Boulé
Stéphane Boulé
JHJean-Sylvain Hermida
Jean-Sylvain Hermida
ADAlexandre Doucy
Alexandre Doucy
PMPhilippe Mabo
Philippe Mabo
DLDominique Lacroix
Dominique Lacroix
Studies assessing radiofrequency ablation (RFA) of ventricular tachycardia (VT) in arrhythmogenic right ventricular cardiomyopathy (ARVC) report VT recurrences, but have not evaluated the impact of RFA on relevant clinical events during follow-up. We aimed to investigate relevant RFA outcomes in a multicentric registry. This study included 49 patients with ARVC (46 with definite diagnosis, 3 with borderline diagnosis according to revised Task Force Criteria) who underwent 92 RFA procedures (83 endocardial, 9 combined endo–epicardial) between 1999–2015. Ventricular tachycardia recurrences and VT burden were assessed after each procedure or after the last RFA. Over a mean follow-up of 64 ± 51 months, VT-free survival was 37% at 1 year, 19% at 5 years, and 14% at 10 years. Ventricular tachycardia burden was significantly reduced after one procedure (23 vs. 11 VT episodes/year, P < 0.01) and after the last RFA (14 vs. 2 VT episodes/year, P < 0.01). Over a mean follow-up of 49 ± 52 months, clinical response after the last RFA (freedom from sudden cardiac death, VT requiring hospitalization, or heart transplantation) was 86% at 1 year, 69% at 5 years, and 60% at 10 years. Clinical response was associated with right ventricular dysfunction (RVD) and low numbers of mappable VT before the first RFA. RFA was predominantly targeted at the endocardial surface. Ventricular tachycardia recurrences were common, but few ARVC patients experienced major clinical events during follow-up. Further studies should investigate the benefit of extensive substrate ablation combined with endo–epicardial strategies.

13 December 2013 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
FBFanny Boudghène-Stambouli
Fanny Boudghène-Stambouli
SBStéphane Boulé
Stéphane Boulé
CGCéline Goéminne
Céline Goéminne
EBEdward Botcherby
Edward Botcherby
CMChristelle Marquié
Christelle Marquié
SKSalem Kacet
Salem Kacet

1 November 2012 in International Journal of Cardiology
Verified
Journal Article
Closed access
SBStéphane Boulé
Stéphane Boulé
VFVeronique Fressart
Veronique Fressart
DLDaniela Laux
Daniela Laux
AMAudrey Mallet
Audrey Mallet
FSFrancoise Simon
Francoise Simon
PCPhilippe Charron
Philippe Charron

20 March 2012 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
SBStéphane Boulé
Stéphane Boulé
CMChristelle Marquié
Christelle Marquié
CVClaire Vanesson‐Bricout
Claire Vanesson‐Bricout
CKClaude Kouakam
Claude Kouakam
FBFrançois Brigadeau
François Brigadeau
SKSalem Kacet
Salem Kacet